Good points. In other words, pfe is being viewed by the street as a Sears of the 1980's and 90's, and mrk is being viewed as an Abercrombie. The thing is that all large cap.pharma should be having, by reason of their size, the same difficulties discovering and bringing new products to market. What I am seeing is that not all large cap. pharma are created equal. Now we are seeing that some large pharma are executing better than others. Unfortunately for pfe., this is "the other".